Engrail Therapeutics

Focus: Engrail Therapeutics is a San Diego-based biotech focused on neurology treatments for life-limiting diseases, currently in early clinical stages with no approved products.

Neurology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Engrail Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Engrail Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ENX-205

Healthy Volunteer

PHASE_1

Clinical Trials (1)

NCT07253246ENX-205 SAD/PET Study in Healthy Adults

Phase 1

Help build intelligence for Engrail Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline in high-need neurology indications (epilepsy, depression, anxiety) with multiple Phase 2 programs offering meaningful R&D impact
Public company status provides stability and equity upside potential compared to private venture-backed peers
Focused therapeutic area allows for deep specialization and close collaboration across a small, mission-driven team

Watch Out For

Zero active job openings and no disclosed employee count signal minimal near-term hiring or possible organizational constraints
Entirely pre-revenue pipeline with no Phase 3 programs means 5+ years minimum to first potential approval, with significant clinical and regulatory risk

Generated by Claude from Engrail Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ENX-104

Healthy Volunteers

PHASE_1

Clinical Trials (2)

NCT07253272A PET Study of ENX-104 in Healthy Volunteers

Phase 1

NCT07472361A Study of ENX-104 in Healthy Participants

Phase 1

ENX-104

Major Depressive Disorder

PHASE_1

Clinical Trials (1)

NCT07253324ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD)

Phase 1

ENX-102

Generalized Anxiety Disorder

PHASE_2

Clinical Trials (1)

NCT05749055ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

Phase 2

ENX-102

Social Anxiety Disorder (SAD)

PHASE_2

Clinical Trials (1)

NCT07193563A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

Phase 2

ENX-101

Focal Epilepsy

PHASE_2

Clinical Trials (1)

NCT05481905ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

Phase 2

ENX-102

General Anxiety Disorder

PHASE_2

Clinical Trials (1)

NCT06653296A Dose-Response Safety Study of ENX-102 in Patients With GAD

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2019

Portfolio: 8 clinical trials

Top TAs: Neurology

Publications: 9 in PubMed

Therapeutic Area Focus

Neurology

4 pipeline

Marketed

Pipeline

Research Publications(9)

Recent peer-reviewed publications with author affiliations at this company

Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia.

Schizophrenia research

2026

PMID:41825117

Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial.

International clinical psychopharmacology

2026

PMID:40694062

Showing 5 of 9 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo